论文部分内容阅读
目的 探讨CD54,CD80,CD86和HLA-ABC在肝硬变的免疫损伤和抗肝癌免疫中的意义。 方法 用免疫组化方法检测CD54,CD80,CD86和HLA-ABC在肝硬变(n=30)和肝癌(n=48)中的表达、定位和分布。 结果 在LC中,CD54阳性率为40％(12/30),CD80为50％(15/30),CD86为37％(11/30),HLA-ABC为63％(19/30);在HCC中,CD54阳性率为77％(37/48),CD80为19％(9/47),CD86为13％(6/47),HLA-ABC为30％(12/40);在癌周围组织(PCT)中,CD54为阴性,CD80阳性率为44％(14/32),CD86为47％(15/32),HLA-ABC为53％(17/32),统计学处理显示,在LC中,CD54阳性率显著低于HCC(P<0.01);CD80(P<0.01),CD86(F<0.05)和HLA-ABC(P<0.01)均显著高于HCA;而与PCT无显著差别,在HCC中,CD80(P<0.05),CD86(P<0.01),HLA-ABC(P<0.05),均显著低于PCT。 结论 CD54,CD80,CD86和HLA-ABC在LC和HCA3中的同时足量表达有可能引起肝细胞损伤和有效抗肿瘤免疫应答,而CD80,CD86表达的缺失或不足可能是HCC产生免疫逃避的主要原因。
Objective To investigate the significance of CD54, CD80, CD86 and HLA-ABC in the immunological injury of liver cirrhosis and anti-liver cancer immunity. Methods The expression, localization and distribution of CD54, CD80, CD86 and HLA-ABC in cirrhosis (n = 30) and liver cancer (n = 48) were detected by immunohistochemistry. Results In LC, the positive rate of CD54 was 40% (12/30), CD80 was 50% (15/30), CD86 was 37% (11/30) and HLA-ABC was 63% In HCC, the positive rate of CD54 was 77% (37/48), CD80 was 19% (9/47), CD86 was 13% (6/47) and HLA-ABC was 30% (12/40) CD54 was 47% (15/32), and HLA-ABC was 53% (17/32). The results of statistical analysis showed that the positive rate of CD54 was LC, the positive rate of CD54 was significantly lower than that of HCC (P <0.01); CD80 (P <0.01), CD86 (F < CD80 (P <0.05), CD86 (P <0.01) and HLA-ABC (P <0.05) in HCC were significantly lower than those in PCT. Conclusions The simultaneous expression of CD54, CD80, CD86 and HLA-ABC in both LC and HCA3 may cause hepatocellular injury and an effective anti-tumor immune response. However, the lack or deficiency of CD80 and CD86 expression may be the major cause of immune evasion in HCC the reason.